{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T04:16:39Z","timestamp":1793506599340,"version":"4.5.0"},"reference-count":210,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011010","name":"European SocieTy for Radiotherapy and Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007075","name":"European Society for Medical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007075","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"Dutch Cancer Society","doi-asserted-by":"publisher","award":["12702"],"award-info":[{"award-number":["12702"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.annonc.2025.09.008","type":"journal-article","created":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T04:21:34Z","timestamp":1758946894000},"page":"17-32","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["ESMO\u2013ESTRO consensus statements on the safety of combining radiotherapy with immune checkpoint inhibitors, VEGF(R) inhibitors, or multitargeted tyrosine kinase inhibitors"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2358-4435","authenticated-orcid":false,"given":"E.S.M.","family":"van Aken","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8465-0905","authenticated-orcid":false,"given":"B.","family":"Devnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Prelaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Castelo-Branco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.A.M.","family":"Marijnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7214-4818","authenticated-orcid":false,"given":"D.","family":"Martins-Branco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.","family":"Gambacorta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Lamarca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6014-348X","authenticated-orcid":false,"given":"K.","family":"Harrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Minniti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2082-216X","authenticated-orcid":false,"given":"M.","family":"Hecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2643-5569","authenticated-orcid":false,"given":"D.","family":"Papamichael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1776-9556","authenticated-orcid":false,"given":"M.","family":"Krause","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Cathomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Lindberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5574-9199","authenticated-orcid":false,"given":"S.M.","family":"O\u2019Cathail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Nestle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Barriuso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Nowicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"R\u00f6del","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Boot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Belka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Ricardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8591-9339","authenticated-orcid":false,"given":"F.","family":"Lordick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"De Ruysscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6632-2462","authenticated-orcid":false,"given":"G.","family":"Pentheroudakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7736-6789","authenticated-orcid":false,"given":"M.C.","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.K.","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annonc.2025.09.008_bib1","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/s41573-023-00723-4","article-title":"Trends in the approval of cancer therapies by the FDA in the twenty-first century","volume":"22","author":"Scott","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.annonc.2025.09.008_bib2","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1200\/JGO.2015.001545","article-title":"Global access to radiotherapy services: have we made progress during the past decade?","volume":"2","author":"Yap","year":"2016","journal-title":"J Glob Oncol"},{"key":"10.1016\/j.annonc.2025.09.008_bib3","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1056\/NEJMra1608986","article-title":"Recent developments in radiotherapy","volume":"377","author":"Citrin","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annonc.2025.09.008_bib4","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41572-019-0064-5","article-title":"Radiotherapy toxicity","volume":"5","author":"De Ruysscher","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.annonc.2025.09.008_bib5","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20160251","article-title":"Stereotactic body radiotherapy for oligoprogressive cancer","volume":"89","author":"Cheung","year":"2016","journal-title":"Br J Radiol"},{"key":"10.1016\/j.annonc.2025.09.008_bib6","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.radonc.2020.04.003","article-title":"Defining oligometastatic disease from a radiation oncology perspective: an ESTRO-ASTRO consensus document","volume":"148","author":"Lievens","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.annonc.2025.09.008_bib7","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1002\/cncr.22555","article-title":"A review of hypofractionated palliative radiotherapy","volume":"109","author":"Lutz","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.annonc.2025.09.008_bib8","first-page":"93","article-title":"Hypofractionated radiotherapy combined with targeted therapy or immunotherapy: Dutch survey on current practice, knowledge and challenges","volume":"33","author":"van Aken","year":"2022","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.annonc.2025.09.008_bib9","article-title":"Unexpected toxicity of CDK4\/6 inhibitor palbociclib and radiotherapy","volume":"5","author":"van Aken","year":"2022","journal-title":"Cancer Rep (Hoboken)"},{"key":"10.1016\/j.annonc.2025.09.008_bib10","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1158\/1078-0432.CCR-20-2551","article-title":"Phase I and pharmacologic study of olaparib in combination with high-dose radiotherapy with and without concurrent cisplatin for non-small cell lung cancer","volume":"27","author":"de Haan","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2025.09.008_bib11","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1093\/annonc\/mdv139","article-title":"Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patients","volume":"26","author":"Hecht","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2025.09.008_bib12","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1200\/JCO.2013.49.3528","article-title":"Cutis verticis gyrata in association with vemurafenib and whole-brain radiotherapy","volume":"32","author":"Harding","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2025.09.008_bib13","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ijrobp.2013.05.012","article-title":"Increased bowel toxicity in patients treated with a vascular endothelial growth factor inhibitor (VEGFI) after stereotactic body radiation therapy (SBRT)","volume":"87","author":"Barney","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.annonc.2025.09.008_bib14","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1200\/JCO.2007.15.8451","article-title":"Bowel perforation after radiotherapy in a patient receiving sorafenib","volume":"26","author":"Peters","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2025.09.008_bib15","doi-asserted-by":"crossref","first-page":"4780","DOI":"10.3390\/cancers13194780","article-title":"Continued versus interrupted targeted therapy during metastasis-directed stereotactic radiotherapy: a retrospective multi-center safety and efficacy analysis","volume":"13","author":"Kroeze","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.annonc.2025.09.008_bib16","doi-asserted-by":"crossref","first-page":"6298","DOI":"10.1158\/1078-0432.CCR-11-1468","article-title":"Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design","volume":"17","author":"Chaft","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2025.09.008_bib17","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/JTO.0b013e318257fc1d","article-title":"Disease flare after treatment discontinuation in a patient with EML4-ALK lung cancer and acquired resistance to crizotinib","volume":"7","author":"Pop","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.annonc.2025.09.008_bib18","article-title":"Tumor flare of brain metastases upon dose interruption of sunitinib in a patient with metastatic renal cell carcinoma","volume":"27","author":"Amirault","year":"2021","journal-title":"Cancer Treat Res Commun"},{"key":"10.1016\/j.annonc.2025.09.008_bib19","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/COC.0000000000000501","article-title":"Concurrent radiation and immunotherapy: survey of practice patterns in the United States","volume":"42","author":"Amin","year":"2019","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.annonc.2025.09.008_bib20","doi-asserted-by":"crossref","first-page":"7624","DOI":"10.1038\/s41598-021-86863-2","article-title":"Evaluation of practical experiences of German speaking radiation oncologists in combining radiation therapy with checkpoint blockade","volume":"11","author":"Kraus","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.annonc.2025.09.008_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2025.110910","article-title":"ESMO-ESTRO framework for assessing the interactions and safety of combining radiotherapy with targeted cancer therapies or immunotherapy","volume":"208","author":"van Aken","year":"2025","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.annonc.2025.09.008_bib22","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s00280-019-03806-5","article-title":"Safety assessment of anticancer drugs in association with radiotherapy in metastatic malignant melanoma: a real-life report: radiation\/systemic drug combo in metastatic melanoma","volume":"83","author":"Couty","year":"2019","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.annonc.2025.09.008_bib23","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/CAD.0000000000000349","article-title":"Safety assessment of molecular targeted therapies in association with radiotherapy in metastatic renal cell carcinoma: a real-life report","volume":"27","author":"Langrand-Escure","year":"2016","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.annonc.2025.09.008_bib24","series-title":"StatPearls [Internet]. Treasure Island, FL","article-title":"Half life","author":"Hallare","year":"2023"},{"key":"10.1016\/j.annonc.2025.09.008_bib25","series-title":"Applied Biopharmaceutics & Pharmacokinetics","author":"Shargel","year":"2016"},{"key":"10.1016\/j.annonc.2025.09.008_bib26","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/S1470-2045(23)00534-X","article-title":"International multidisciplinary consensus on the integration of radiotherapy with new systemic treatments for breast cancer: European Society for Radiotherapy and Oncology (ESTRO)-endorsed recommendations","volume":"25","author":"Meattini","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2025.09.008_bib27","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1086\/321805","article-title":"Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients","volume":"33","author":"Dykewicz","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.annonc.2025.09.008_bib28","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1093\/clinids\/18.3.421","article-title":"Purpose of quality standards for infectious diseases. Infectious Diseases Society of America","volume":"18","author":"Gross","year":"1994","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.annonc.2025.09.008_bib29","doi-asserted-by":"crossref","first-page":"116","DOI":"10.5662\/wjm.v11.i4.116","article-title":"Delphi methodology in healthcare research: how to decide its appropriateness","volume":"11","author":"Nasa","year":"2021","journal-title":"World J Methodol"},{"key":"10.1016\/j.annonc.2025.09.008_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.techfore.2020.120484","article-title":"Consensus in the Delphi method: what makes a decision change?","volume":"163","author":"Barrios","year":"2021","journal-title":"Technol Forecast Soc Change"},{"key":"10.1016\/j.annonc.2025.09.008_bib31","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Br Med J"},{"key":"10.1016\/j.annonc.2025.09.008_bib32","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental mechanisms of immune checkpoint blockade therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.annonc.2025.09.008_bib33","doi-asserted-by":"crossref","first-page":"848.e1","DOI":"10.1016\/j.ccell.2017.05.010","article-title":"SnapShot: immune checkpoint inhibitors","volume":"31","author":"Abril-Rodriguez","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.annonc.2025.09.008_bib34","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/s41392-020-00348-8","article-title":"Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy","volume":"5","author":"Cao","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.annonc.2025.09.008_bib35","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2025.09.008_bib36","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.jaad.2020.10.071","article-title":"Incidence of dermatologic adverse events in patients with cancer treated with concurrent immune checkpoint inhibitors and radiation therapy: a systematic review and meta-analysis","volume":"84","author":"Yan","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annonc.2025.09.008_bib37","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejca.2020.09.008","article-title":"Avelumab-cetuximab-radiotherapy versus standards of care in locally advanced squamous-cell carcinoma of the head and neck: the safety phase of a randomised phase III trial GORTEC 2017-01 (REACH)","volume":"141","author":"Tao","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annonc.2025.09.008_bib38","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S1470-2045(14)70189-5","article-title":"Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial","volume":"15","author":"Kwon","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2025.09.008_bib39","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annonc.2025.09.008_bib40","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.ijrobp.2018.04.054","article-title":"Safety of combined immunotherapy and thoracic radiation therapy: analysis of 3 single-institutional phase I\/II trials","volume":"101","author":"Verma","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.annonc.2025.09.008_bib41","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.lungcan.2019.05.001","article-title":"Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer - the ETOP NICOLAS trial","volume":"133","author":"Peters","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.annonc.2025.09.008_bib42","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001001","article-title":"Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I\/II trial","volume":"8","author":"Welsh","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.annonc.2025.09.008_bib43","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1158\/2326-6066.CIR-18-0793","article-title":"Phase II trial of ipilimumab with stereotactic radiation therapy for metastatic disease: outcomes, toxicities, and low-dose radiation-related abscopal responses","volume":"7","author":"Welsh","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.annonc.2025.09.008_bib44","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1684\/ejd.2019.3671","article-title":"Pembrolizumab and concurrent hypo-fractionated radiotherapy for advanced non-resectable cutaneous squamous cell carcinoma","volume":"29","author":"Lavaud","year":"2019","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.annonc.2025.09.008_bib45","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1093\/neuonc\/noaa260","article-title":"Hypofractionated stereotactic re-irradiation with pembrolizumab and bevacizumab in patients with recurrent high-grade gliomas: results from a phase I study","volume":"23","author":"Sahebjam","year":"2021","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.annonc.2025.09.008_bib46","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ejca.2016.09.013","article-title":"Concurrent irradiation with the anti-programmed cell death ligand-1 immune checkpoint blocker durvalumab: single centre subset analysis from a phase 1\/2 trial","volume":"68","author":"Levy","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annonc.2025.09.008_bib47","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.3390\/cancers12092429","article-title":"Addition of radiotherapy to immunotherapy: effects on outcome of different subgroups using a propensity score matching","volume":"12","author":"Trommer","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.annonc.2025.09.008_bib48","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s12094-018-02005-7","article-title":"Benefit of ablative versus palliative-only radiotherapy in combination with nivolumab in patients affected by metastatic kidney and lung cancer","volume":"21","author":"Desideri","year":"2019","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.annonc.2025.09.008_bib49","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ijrobp.2017.05.028","article-title":"Phase 1 study of ipilimumab combined with whole brain radiation therapy or radiosurgery for melanoma patients with brain metastases","volume":"99","author":"Williams","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.annonc.2025.09.008_bib50","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s11060-014-1617-9","article-title":"Ipilimumab and whole brain radiation therapy for melanoma brain metastases","volume":"121","author":"Gerber","year":"2015","journal-title":"J Neurooncol"},{"key":"10.1016\/j.annonc.2025.09.008_bib51","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11060-018-2933-2","article-title":"Stereotactic radiosurgery for brain metastases from malignant melanoma and the impact of hemorrhagic metastases","volume":"140","author":"Bauer-Nilsen","year":"2018","journal-title":"J Neurooncol"},{"key":"10.1016\/j.annonc.2025.09.008_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2019.106148","article-title":"Hypofractionated radiation therapy with versus without immune checkpoint inhibitors in patients with brain metastases: a meta-analysis","volume":"80","author":"Yang","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.annonc.2025.09.008_bib53","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.3389\/fonc.2020.01609","article-title":"Quantification of scheduling impact on safety and efficacy outcomes of brain metastasis radio- and immuno-therapies: a systematic review and meta-analysis","volume":"10","author":"Voronova","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.annonc.2025.09.008_bib54","doi-asserted-by":"crossref","first-page":"5909","DOI":"10.21037\/tcr-20-902","article-title":"Intracranial radiotherapy with or without immune checkpoint inhibition for brain metastases: a systematic review and meta-analysis","volume":"9","author":"He","year":"2020","journal-title":"Transl Cancer Res"},{"key":"10.1016\/j.annonc.2025.09.008_bib55","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s13014-020-01644-x","article-title":"Immune checkpoint inhibition in patients treated with stereotactic radiation for brain metastases","volume":"15","author":"Kowalski","year":"2020","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.annonc.2025.09.008_bib56","first-page":"402","article-title":"Immunotherapy is associated with improved survival and decreased neurologic death after SRS for brain metastases from lung and melanoma primaries","volume":"6","author":"Lanier","year":"2019","journal-title":"Neurooncol Pract"},{"key":"10.1016\/j.annonc.2025.09.008_bib57","first-page":"297","article-title":"Acute neurologic toxicity of palliative radiotherapy for brain metastases in patients receiving immune checkpoint blockade","volume":"6","author":"Arscott","year":"2019","journal-title":"Neurooncol Pract"},{"key":"10.1016\/j.annonc.2025.09.008_bib58","doi-asserted-by":"crossref","first-page":"4260","DOI":"10.1158\/1078-0432.CCR-20-0230","article-title":"Concurrent definitive immunoradiotherapy for patients with stage III-IV head and neck cancer and cisplatin contraindication","volume":"26","author":"Weiss","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2025.09.008_bib59","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.ijrobp.2019.03.041","article-title":"Phase 2 trial of nivolumab combined with stereotactic body radiation therapy in patients with metastatic or locally advanced inoperable melanoma","volume":"104","author":"Sundahl","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.annonc.2025.09.008_bib60","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1089\/thy.2019.0086","article-title":"A phase 2 study of pembrolizumab combined with chemoradiotherapy as initial treatment for anaplastic thyroid cancer","volume":"29","author":"Chintakuntlawar","year":"2019","journal-title":"Thyroid"},{"key":"10.1016\/j.annonc.2025.09.008_bib61","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1158\/1078-0432.CCR-20-2452","article-title":"Ipilimumab and radiation in patients with high-risk resected or regionally advanced melanoma","volume":"27","author":"Salama","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2025.09.008_bib62","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s13566-018-0352-9","article-title":"Tolerability of sequential immune therapy and palliative radiotherapy to the cervical and thoracic spine","volume":"7","author":"Arscott","year":"2018","journal-title":"J Radiat Oncol"},{"key":"10.1016\/j.annonc.2025.09.008_bib63","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annonc.2025.09.008_bib64","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S1470-2045(19)30519-4","article-title":"Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study","volume":"20","author":"Hui","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2025.09.008_bib65","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1200\/JCO.20.00290","article-title":"Randomized phase II trial of nivolumab with stereotactic body radiotherapy versus nivolumab alone in metastatic head and neck squamous cell carcinoma","volume":"39","author":"McBride","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2025.09.008_bib66","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1002\/cncr.32599","article-title":"A phase 2 clinical trial assessing the efficacy and safety of pembrolizumab and radiotherapy in patients with metastatic triple-negative breast cancer","volume":"126","author":"Ho","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.annonc.2025.09.008_bib67","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.clbc.2020.01.012","article-title":"A phase II study of pembrolizumab in combination with palliative radiotherapy for hormone receptor-positive metastatic breast cancer","volume":"20","author":"Barroso-Sousa","year":"2020","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.annonc.2025.09.008_bib68","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1158\/1078-0432.CCR-16-1432","article-title":"Ipilimumab with stereotactic ablative radiation therapy: phase I results and immunologic correlates from peripheral T cells","volume":"23","author":"Tang","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2025.09.008_bib69","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.radonc.2020.05.051","article-title":"Interaction between lymphopenia, radiotherapy technique, dosimetry, and survival outcomes in lung cancer patients receiving combined immunotherapy and radiotherapy","volume":"150","author":"Chen","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.annonc.2025.09.008_bib70","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.adro.2018.05.001","article-title":"Safety of combining thoracic radiation therapy with concurrent versus sequential immune checkpoint inhibition","volume":"3","author":"von Reibnitz","year":"2018","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.annonc.2025.09.008_bib71","doi-asserted-by":"crossref","first-page":"4948","DOI":"10.1002\/cncr.33136","article-title":"Results of an early safety analysis of a study of the combination of pembrolizumab and pelvic chemoradiation in locally advanced cervical cancer","volume":"126","author":"Duska","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.annonc.2025.09.008_bib72","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s13566-020-00419-x","article-title":"Safety of nivolumab in combination with prior or concurrent radiation therapy in hepatocellular carcinoma","volume":"9","author":"Smith","year":"2020","journal-title":"J Radiat Oncol"},{"key":"10.1016\/j.annonc.2025.09.008_bib73","doi-asserted-by":"crossref","first-page":"6986","DOI":"10.1002\/cam4.2570","article-title":"Clinical significance of radiotherapy before and\/or during nivolumab treatment in hepatocellular carcinoma","volume":"8","author":"Yu","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.annonc.2025.09.008_bib74","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.1634\/theoncologist.2018-0205","article-title":"Dramatic response to concurrent anti-PD-1 therapy and radiation in resistant tumors with sarcomatoid differentiation","volume":"24","author":"Tolay","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.annonc.2025.09.008_bib75","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.eururo.2020.07.032","article-title":"Final analysis of the ipilimumab versus placebo following radiotherapy phase III trial in postdocetaxel metastatic castration-resistant prostate cancer identifies an excess of long-term survivors","volume":"78","author":"Fizazi","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.annonc.2025.09.008_bib76","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1158\/1078-0432.CCR-19-3624","article-title":"Immune checkpoint blockade in combination with stereotactic body radiotherapy in patients with metastatic pancreatic ductal adenocarcinoma","volume":"26","author":"Xie","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2025.09.008_bib77","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1093\/annonc\/mdt107","article-title":"Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I\/II study","volume":"24","author":"Slovin","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2025.09.008_bib78","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.18632\/oncotarget.26893","article-title":"Phase I study of local radiation and tremelimumab in patients with inoperable locally recurrent or metastatic breast cancer","volume":"10","author":"Jiang","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.annonc.2025.09.008_bib79","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ijrobp.2020.05.022","article-title":"Stereotactic radiation therapy combined with immunotherapy against metastatic melanoma: long-term results of a phase 1 clinical trial","volume":"108","author":"Ratnayake","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.annonc.2025.09.008_bib80","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1158\/1078-0432.CCR-19-3936","article-title":"A prospective, phase 1 trial of nivolumab, ipilimumab, and radiotherapy in patients with advanced melanoma","volume":"26","author":"Postow","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2025.09.008_bib81","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nrc2403","article-title":"VEGF-targeted therapy: mechanisms of anti-tumour activity","volume":"8","author":"Ellis","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.annonc.2025.09.008_bib82","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10456-009-9160-6","article-title":"Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?","volume":"13","author":"Gotink","year":"2010","journal-title":"Angiogenesis"},{"key":"10.1016\/j.annonc.2025.09.008_bib83","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1038\/nm1101-1194","article-title":"Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth","volume":"7","author":"Lyden","year":"2001","journal-title":"Nat Med"},{"key":"10.1016\/j.annonc.2025.09.008_bib84","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/nrc925","article-title":"Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy?","volume":"2","author":"Rafii","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.annonc.2025.09.008_bib85","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1126\/science.1104819","article-title":"Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy","volume":"307","author":"Jain","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.annonc.2025.09.008_bib86","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1038\/sj.bjc.6603813","article-title":"Mechanisms of adverse effects of anti-VEGF therapy for cancer","volume":"96","author":"Kamba","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1016\/j.annonc.2025.09.008_bib87","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1308345","article-title":"Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma","volume":"370","author":"Chinot","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annonc.2025.09.008_bib88","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1093\/neuonc\/nov300","article-title":"Bevacizumab, temozolomide, and radiotherapy for newly diagnosed glioblastoma: comprehensive safety results during and after first-line therapy","volume":"18","author":"Saran","year":"2016","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.annonc.2025.09.008_bib89","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20140800","article-title":"Late toxicities and outcomes of adjuvant radiotherapy combined with concurrent bevacizumab in patients with triple-negative non-metastatic breast cancer","volume":"88","author":"Pernin","year":"2015","journal-title":"Br J Radiol"},{"key":"10.1016\/j.annonc.2025.09.008_bib90","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1093\/annonc\/mdw204","article-title":"Phase II randomized trial of radiation therapy, cetuximab, and pemetrexed with or without bevacizumab in patients with locally advanced head and neck cancer","volume":"27","author":"Argiris","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2025.09.008_bib91","doi-asserted-by":"crossref","first-page":"461","DOI":"10.2478\/raon-2020-0043","article-title":"Influence of concurrent capecitabine based chemoradiotherapy with bevacizumab on the survival rate, late toxicity and health-related quality of life in locally advanced rectal cancer: a prospective phase II CRAB trial","volume":"54","author":"Velenik","year":"2020","journal-title":"Radiol Oncol"},{"key":"10.1016\/j.annonc.2025.09.008_bib92","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/1748-717X-6-105","article-title":"Neoadjuvant capecitabine, radiotherapy, and bevacizumab (CRAB) in locally advanced rectal cancer: results of an open-label phase II study","volume":"6","author":"Velenik","year":"2011","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.annonc.2025.09.008_bib93","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1159\/000367972","article-title":"Phase II study of preoperative concurrent chemoradiotherapy with S-1 plus bevacizumab for locally advanced resectable rectal adenocarcinoma","volume":"88","author":"Sadahiro","year":"2015","journal-title":"Oncology"},{"key":"10.1016\/j.annonc.2025.09.008_bib94","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1159\/000480295","article-title":"An intergroup randomized phase II study of bevacizumab or cetuximab in combination with gemcitabine and in combination with chemoradiation in patients with resected pancreatic carcinoma: a trial of the ECOG-ACRIN Cancer Research Group (E2204)","volume":"94","author":"Berlin","year":"2018","journal-title":"Oncology"},{"key":"10.1016\/j.annonc.2025.09.008_bib95","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.1245\/s10434-013-3161-9","article-title":"Phase II study of induction fixed-dose rate gemcitabine and bevacizumab followed by 30 Gy radiotherapy as preoperative treatment for potentially resectable pancreatic adenocarcinoma","volume":"20","author":"Van Buren","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.annonc.2025.09.008_bib96","first-page":"430","article-title":"A phase II trial of preoperative concurrent chemotherapy\/radiation therapy plus bevacizumab\/erlotinib in the treatment of localized esophageal cancer","volume":"10","author":"Bendell","year":"2012","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.annonc.2025.09.008_bib97","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.1158\/1078-0432.CCR-11-0120","article-title":"The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma","volume":"17","author":"Vredenburgh","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2025.09.008_bib98","first-page":"49","article-title":"A network meta-analysis of treatment for newly diagnosed glioblastoma based on radiotherapy plus temozolomide","volume":"22","author":"Zheng","year":"2017","journal-title":"Neurol Asia"},{"key":"10.1016\/j.annonc.2025.09.008_bib99","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3727\/096504016X14612603423511","article-title":"Molecularly targeted drugs plus radiotherapy and temozolomide treatment for newly diagnosed glioblastoma: a meta-analysis and systematic review","volume":"24","author":"Su","year":"2016","journal-title":"Oncol Res"},{"key":"10.1016\/j.annonc.2025.09.008_bib100","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1093\/neuonc\/now091","article-title":"Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy\/temozolomide for newly diagnosed glioblastoma","volume":"18","author":"Wick","year":"2016","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.annonc.2025.09.008_bib101","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1093\/annonc\/mdu148","article-title":"Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF","volume":"25","author":"Chauffert","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2025.09.008_bib102","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s11060-016-2357-9","article-title":"Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas","volume":"132","author":"Nayak","year":"2017","journal-title":"J Neurooncol"},{"key":"10.1016\/j.annonc.2025.09.008_bib103","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s11060-020-03551-3","article-title":"Repeat radiation with bevacizumab and minocycline in bevacizumab-refractory high grade gliomas: a prospective phase 1 trial","volume":"148","author":"Cohen","year":"2020","journal-title":"J Neurooncol"},{"key":"10.1016\/j.annonc.2025.09.008_bib104","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s11060-010-0390-7","article-title":"Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide","volume":"103","author":"Gerstner","year":"2011","journal-title":"J Neurooncol"},{"key":"10.1016\/j.annonc.2025.09.008_bib105","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1093\/annonc\/mdu465","article-title":"REBECA: a phase I study of bevacizumab and whole-brain radiation therapy for the treatment of brain metastasis from solid tumours","volume":"25","author":"Levy","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2025.09.008_bib106","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1634\/theoncologist.2013-0101","article-title":"Low incidence of pseudoprogression by imaging in newly diagnosed glioblastoma patients treated with cediranib in combination with chemoradiation","volume":"19","author":"Pinho","year":"2014","journal-title":"Oncologist"},{"key":"10.1016\/j.annonc.2025.09.008_bib107","first-page":"48","article-title":"Large volume re-irradiation with bevacizumab is a feasible salvage option for patients with refractory high-grade glioma","volume":"2","author":"Back","year":"2015","journal-title":"Neurooncol Pract"},{"key":"10.1016\/j.annonc.2025.09.008_bib108","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3171\/2018.8.JNS182100","article-title":"Overall survival and response to radiation and targeted therapies among patients with renal cell carcinoma brain metastases","volume":"132","author":"Juloori","year":"2019","journal-title":"J Neurosurg"},{"key":"10.1016\/j.annonc.2025.09.008_bib109","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.2147\/OTT.S80159","article-title":"Bevacizumab plus cisplatin and helical tomotherapy in treatment of locally advanced nasopharyngeal carcinoma","volume":"8","author":"Li","year":"2015","journal-title":"Onco Targets Ther"},{"issue":"suppl 1","key":"10.1016\/j.annonc.2025.09.008_bib110","first-page":"E566","article-title":"Phase II trial of bevacizumab + cetuximab + cisplatin with concurrent intensity-modulated radiation therapy for patients with stage III\/IVB head and neck squamous cell carcinoma","volume":"38","author":"Fury","year":"2016","journal-title":"Head Neck"},{"key":"10.1016\/j.annonc.2025.09.008_bib111","doi-asserted-by":"crossref","first-page":"828","DOI":"10.21037\/jgo.2016.08.09","article-title":"Phase II study of bevacizumab and preoperative chemoradiation for esophageal adenocarcinoma","volume":"7","author":"Ku","year":"2016","journal-title":"J Gastrointest Oncol"},{"key":"10.1016\/j.annonc.2025.09.008_bib112","doi-asserted-by":"crossref","first-page":"423","DOI":"10.5301\/tj.5000701","article-title":"Increased efficacy of stereotactic ablative radiation therapy after bevacizumab in lung oligometastases from colon cancer","volume":"104","author":"Mazzola","year":"2018","journal-title":"Tumori"},{"key":"10.1016\/j.annonc.2025.09.008_bib113","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1200\/JCO.2009.24.7353","article-title":"Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab","volume":"28","author":"Spigel","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2025.09.008_bib114","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1200\/JCO.2011.38.4552","article-title":"Pulmonary toxicity after bevacizumab and concurrent thoracic radiotherapy observed in a phase I study for inoperable stage III non-small-cell lung cancer","volume":"30","author":"Lind","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2025.09.008_bib115","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1200\/JCO.2007.14.5466","article-title":"Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil","volume":"27","author":"Reck","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2025.09.008_bib116","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.jtho.2021.03.019","article-title":"The HILUS-trial-a prospective Nordic multicenter phase 2 study of ultracentral lung tumors treated with stereotactic body radiotherapy","volume":"16","author":"Lindberg","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.annonc.2025.09.008_bib117","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1001\/jamaoncol.2019.0205","article-title":"Analysis of toxic effects with antiangiogenic agents plus stereotactic body radiation in ultracentral lung tumors","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.annonc.2025.09.008_bib118","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1080\/07357907.2017.1344700","article-title":"A phase 2 study of 5-fluorouracil (5-FU), ziv-aflibercept, and radiation for the preoperative and adjuvant treatment of patients with stage II\/III rectal cancer","volume":"35","author":"Bendell","year":"2017","journal-title":"Cancer Invest"},{"key":"10.1016\/j.annonc.2025.09.008_bib119","article-title":"Apatinib combined with chemotherapy or concurrent chemo-brachytherapy in patients with recurrent or advanced cervical cancer: a phase 2, randomized controlled, prospective study","volume":"99","author":"Guo","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.annonc.2025.09.008_bib120","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.ijrobp.2010.07.024","article-title":"Phase II study of neoadjuvant bevacizumab and radiotherapy for resectable soft tissue sarcomas","volume":"81","author":"Yoon","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.annonc.2025.09.008_bib121","doi-asserted-by":"crossref","first-page":"416","DOI":"10.3171\/2017.8.SPINE17162","article-title":"Myositis following spine radiosurgery for metastatic disease: a case series","volume":"28","author":"Lockney","year":"2018","journal-title":"J Neurosurg Spine"},{"key":"10.1016\/j.annonc.2025.09.008_bib122","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1097\/CAD.0000000000000204","article-title":"Safety of spinal radiotherapy in metastatic cancer patients receiving bevacizumab therapy: a bi-institutional case series","volume":"26","author":"Mbagui","year":"2015","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.annonc.2025.09.008_bib123","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s11523-024-01067-8","article-title":"Anti-angiogenic tyrosine kinase inhibitor-related toxicities among cancer patients: a systematic review and meta-analysis","volume":"19","author":"Van Nguyen","year":"2024","journal-title":"Target Oncol"},{"key":"10.1016\/j.annonc.2025.09.008_bib124","doi-asserted-by":"crossref","first-page":"e559","DOI":"10.1097\/MJT.0000000000000649","article-title":"Radiation recall dermatitis consecutive to cabozantinib use","volume":"26","author":"Kumar","year":"2019","journal-title":"Am J Ther"},{"key":"10.1016\/j.annonc.2025.09.008_bib125","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/cncr.29798","article-title":"Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas","volume":"122","author":"Schiff","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.annonc.2025.09.008_bib126","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.mayocpiqo.2019.04.002","article-title":"Esophageal stricture following radiation, concurrent immunochemotherapy, treated with hyperbaric oxygen and dilation","volume":"3","author":"Ajayi","year":"2019","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"key":"10.1016\/j.annonc.2025.09.008_bib127","doi-asserted-by":"crossref","first-page":"4202","DOI":"10.1200\/JCO.2015.61.4370","volume":"33","author":"Harrington","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2025.09.008_bib128","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1093\/annonc\/mdn759","article-title":"Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens","volume":"20","author":"Blackwell","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2025.09.008_bib129","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s10549-013-2754-0","article-title":"A phase I study of lapatinib with whole brain radiotherapy in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer brain metastases","volume":"142","author":"Lin","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.annonc.2025.09.008_bib130","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s11060-017-2548-z","article-title":"Lapatinib with whole brain radiotherapy in patients with brain metastases from breast and non-small cell lung cancer: a phase II study of the Hellenic Cooperative Oncology Group (HeCOG)","volume":"134","author":"Christodoulou","year":"2017","journal-title":"J Neurooncol"},{"key":"10.1016\/j.annonc.2025.09.008_bib131","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s11060-017-2533-6","article-title":"Report of safety of pulse dosing of lapatinib with temozolomide and radiation therapy for newly-diagnosed glioblastoma in a pilot phase II study","volume":"134","author":"Yu","year":"2017","journal-title":"J Neurooncol"},{"key":"10.1016\/j.annonc.2025.09.008_bib132","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1634\/theoncologist.2012-0256","article-title":"Phase I study and biomarker analysis of lapatinib and concurrent radiation for locally advanced breast cancer","volume":"17","author":"Kimple","year":"2012","journal-title":"Oncologist"},{"key":"10.1016\/j.annonc.2025.09.008_bib133","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1200\/JCO.2008.17.5349","article-title":"Phase I study of lapatinib in combination with chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck","volume":"27","author":"Harrington","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2025.09.008_bib134","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/j.ejca.2012.11.023","article-title":"Randomised phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: rationale for future randomised trials in human papilloma virus-negative disease","volume":"49","author":"Harrington","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annonc.2025.09.008_bib135","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s13014-017-0893-x","article-title":"Combined high dose radiation and pazopanib in metastatic renal cell carcinoma: a phase I dose escalation trial","volume":"12","author":"De Wolf","year":"2017","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.annonc.2025.09.008_bib136","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.3109\/0284186X.2015.1037404","article-title":"A phase I study on the combination of neoadjuvant radiotherapy plus pazopanib in patients with locally advanced soft tissue sarcoma of the extremities","volume":"54","author":"Haas","year":"2015","journal-title":"Acta Oncol"},{"key":"10.1016\/j.annonc.2025.09.008_bib137","article-title":"Evaluation of acute locoregional toxicity in patients with breast cancer treated with adjuvant radiotherapy in combination with pazopanib","volume":"2012","author":"Goyal","year":"2012","journal-title":"ISRN Oncol"},{"key":"10.1016\/j.annonc.2025.09.008_bib138","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/S1470-2045(20)30325-9","article-title":"Pathological response in children and adults with large unresected intermediate-grade or high-grade soft tissue sarcoma receiving preoperative chemoradiotherapy with or without pazopanib (ARST1321): a multicentre, randomised, open-label, phase 2 trial","volume":"21","author":"Weiss","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2025.09.008_bib139","first-page":"674","article-title":"Radiation recall dermatitis induced by pazopanib","volume":"36","author":"Azad","year":"2013","journal-title":"Onkologie"},{"key":"10.1016\/j.annonc.2025.09.008_bib140","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/j.1464-410X.2010.09895.x","article-title":"Simultaneous anti-angiogenic therapy and single-fraction radiosurgery in clinically relevant metastases from renal cell carcinoma","volume":"108","author":"Staehler","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.annonc.2025.09.008_bib141","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.ijrobp.2014.01.017","article-title":"Phase 2 study of combined sorafenib and radiation therapy in patients with advanced hepatocellular carcinoma","volume":"88","author":"Chen","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.annonc.2025.09.008_bib142","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.radonc.2017.06.007","article-title":"Phase I dose escalation study of concurrent palliative radiation therapy with sorafenib in three anatomical cohorts (Thorax, Abdomen, Pelvis): the TAP study","volume":"124","author":"Murray","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.annonc.2025.09.008_bib143","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ejca.2017.11.005","article-title":"Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS-mutated rectal cancer: a phase I\/II trial (SAKK 41\/08)","volume":"89","author":"von Moos","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annonc.2025.09.008_bib144","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3857\/roj.2017.00339","article-title":"Radiation recall dermatitis triggered by sorafenib after radiation therapy for hepatocellular carcinoma","volume":"35","author":"Kim","year":"2017","journal-title":"Radiat Oncol J"},{"key":"10.1016\/j.annonc.2025.09.008_bib145","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.2147\/OTT.S64706","article-title":"Recall radiation dermatitis by sorafenib following stereotactic body radiation therapy","volume":"7","author":"Hsieh","year":"2014","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.annonc.2025.09.008_bib146","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3857\/roj.2013.31.3.171","article-title":"Sorafenib-triggered radiation recall dermatitis with a disseminated exanthematous reaction","volume":"31","author":"Oh","year":"2013","journal-title":"Radiat Oncol J"},{"key":"10.1016\/j.annonc.2025.09.008_bib147","article-title":"Radiation recall dermatitis in patients treated with sorafenib","volume":"2018","author":"Mehta","year":"2018","journal-title":"Case Rep Oncol Med"},{"key":"10.1016\/j.annonc.2025.09.008_bib148","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000019660","article-title":"Comparison of stereotactic body radiation therapy with and without sorafenib as treatment for hepatocellular carcinoma with portal vein tumor thrombosis","volume":"99","author":"Que","year":"2020","journal-title":"Medicine"},{"key":"10.1016\/j.annonc.2025.09.008_bib149","doi-asserted-by":"crossref","first-page":"6902","DOI":"10.1158\/1078-0432.CCR-13-1594","article-title":"Phase I trial of preoperative chemoradiation plus sorafenib for high-risk extremity soft tissue sarcomas with dynamic contrast-enhanced MRI correlates","volume":"19","author":"Meyer","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2025.09.008_bib150","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.ijrobp.2012.04.017","article-title":"A phase I study of the combination of sorafenib with temozolomide and radiation therapy for the treatment of primary and recurrent high-grade gliomas","volume":"85","author":"Den","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.annonc.2025.09.008_bib151","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s11060-017-2455-3","article-title":"A phase I trial of concurrent sorafenib and stereotactic radiosurgery for patients with brain metastases","volume":"133","author":"Arneson","year":"2017","journal-title":"J Neurooncol"},{"key":"10.1016\/j.annonc.2025.09.008_bib152","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1245\/s10434-014-3543-7","article-title":"Phase I trial of neoadjuvant conformal radiotherapy plus sorafenib for patients with locally advanced soft tissue sarcoma of the extremity","volume":"21","author":"Canter","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.annonc.2025.09.008_bib153","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.radonc.2016.01.018","article-title":"Phase I study of pre-operative continuous 5-FU and sorafenib with external radiation therapy in locally advanced rectal adenocarcinoma","volume":"118","author":"Kim","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.annonc.2025.09.008_bib154","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.3389\/fonc.2019.01065","article-title":"Safety and efficacy of transcatheter arterial chemoembolization plus radiotherapy combined with sorafenib in hepatocellular carcinoma showing macrovascular invasion","volume":"9","author":"Zhao","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.annonc.2025.09.008_bib155","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annonc.2025.09.008_bib156","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annonc.2025.09.008_bib157","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s11523-013-0280-y","article-title":"Concurrent sunitinib and stereotactic body radiotherapy for patients with oligometastases: final report of a prospective clinical trial","volume":"9","author":"Kao","year":"2014","journal-title":"Target Oncol"},{"key":"10.1016\/j.annonc.2025.09.008_bib158","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.urolonc.2010.02.006","article-title":"Feasibility and effects of high-dose hypofractionated radiation therapy and simultaneous multi-kinase inhibition with sunitinib in progressive metastatic renal cell cancer","volume":"30","author":"Staehler","year":"2012","journal-title":"Urol Oncol"},{"key":"10.1016\/j.annonc.2025.09.008_bib159","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ijrobp.2009.07.1725","article-title":"Angiogenic blockade and radiotherapy in hepatocellular carcinoma","volume":"78","author":"Chi","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.annonc.2025.09.008_bib160","doi-asserted-by":"crossref","first-page":"5548","DOI":"10.1002\/cncr.26216","article-title":"A phase 1b trial of the combination of the antiangiogenic agent sunitinib and radiation therapy for patients with primary and metastatic central nervous system malignancies","volume":"117","author":"Wuthrick","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.annonc.2025.09.008_bib161","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ijrobp.2014.05.034","article-title":"A pilot study of hypofractionated stereotactic radiation therapy and sunitinib in previously irradiated patients with recurrent high-grade glioma","volume":"90","author":"Wuthrick","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.annonc.2025.09.008_bib162","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.ijrobp.2012.12.029","article-title":"Sunitinib plus androgen deprivation and radiation therapy for patients with localized high-risk prostate cancer: results from a multi-institutional phase 1 study","volume":"86","author":"Corn","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.annonc.2025.09.008_bib163","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s11523-014-0305-1","article-title":"Sunitinib administered prior to radiotherapy in patients with non-resectable glioblastoma: results of a phase II study","volume":"9","author":"Balana","year":"2014","journal-title":"Target Oncol"},{"key":"10.1016\/j.annonc.2025.09.008_bib164","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1245\/s10434-015-4680-3","article-title":"Combined radiation therapy and sunitinib for preoperative treatment of soft tissue sarcoma","volume":"22","author":"Jakob","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.annonc.2025.09.008_bib165","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s13014-016-0654-2","article-title":"Combined sunitinib and radiation therapy for preoperative treatment of soft tissue sarcoma: results of a phase I trial of the German Interdisciplinary Sarcoma Group (GISG-03)","volume":"11","author":"Jakob","year":"2016","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.annonc.2025.09.008_bib166","doi-asserted-by":"crossref","first-page":"4762","DOI":"10.1200\/JCO.2010.30.3545","article-title":"Phase I study of vandetanib during and after radiotherapy in children with diffuse intrinsic pontine glioma","volume":"28","author":"Broniscer","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2025.09.008_bib167","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/hed.23922","article-title":"Phase I study of vandetanib with radiation therapy with or without cisplatin in locally advanced head and neck squamous cell carcinoma","volume":"38","author":"Papadimitrakopoulou","year":"2016","journal-title":"Head Neck"},{"key":"10.1016\/j.annonc.2025.09.008_bib168","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ijrobp.2009.07.1741","article-title":"Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma","volume":"78","author":"Drappatz","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.annonc.2025.09.008_bib169","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1038\/bjc.2016.318","article-title":"RADVAN: a randomised phase 2 trial of WBRT plus vandetanib for melanoma brain metastases - results and lessons learnt","volume":"115","author":"Gupta","year":"2016","journal-title":"Br J Cancer"},{"key":"10.1016\/j.annonc.2025.09.008_bib170","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/COC.0000000000000171","article-title":"Induction therapy for locally advanced, resectable esophagogastric cancer: a phase I trial of vandetanib (ZD6474), paclitaxel, carboplatin, 5-fluorouracil, and radiotherapy followed by resection","volume":"40","author":"Boland","year":"2017","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.annonc.2025.09.008_bib171","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.1158\/1078-0432.CCR-14-3220","article-title":"A multicenter, phase II, randomized, noncomparative clinical trial of radiation and temozolomide with or without vandetanib in newly diagnosed glioblastoma patients","volume":"21","author":"Lee","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2025.09.008_bib172","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ijrobp.2010.09.008","article-title":"Phase I dose escalation trial of vandetanib with fractionated radiosurgery in patients with recurrent malignant gliomas","volume":"82","author":"Fields","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.annonc.2025.09.008_bib173","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1200\/JCO.2010.28.5981","article-title":"Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer","volume":"29","author":"Natale","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2025.09.008_bib174","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","article-title":"Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial","volume":"30","author":"Wells","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2025.09.008_bib175","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3171\/2018.10.JNS182340","article-title":"Stereotactic radiosurgery with concurrent lapatinib is associated with improved local control for HER2-positive breast cancer brain metastases","volume":"132","author":"Parsai","year":"2019","journal-title":"J Neurosurg"},{"key":"10.1016\/j.annonc.2025.09.008_bib176","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1093\/neuonc\/noz006","article-title":"Stereotactic radiosurgery with concurrent HER2-directed therapy is associated with improved objective response for breast cancer brain metastasis","volume":"21","author":"Kim","year":"2019","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.annonc.2025.09.008_bib177","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1038\/bjc.2014.209","article-title":"Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma","volume":"110","author":"Hottinger","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.annonc.2025.09.008_bib178","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annonc.2025.09.008_bib179","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s11523-008-0091-8","article-title":"Successful treatment of brain metastases from renal cell cancer using radiotherapy in combination with sorafenib","volume":"3","author":"Stierner","year":"2008","journal-title":"Target Oncol"},{"key":"10.1016\/j.annonc.2025.09.008_bib180","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jtho.2015.11.001","article-title":"Positive interaction between prophylactic cranial irradiation and maintenance sunitinib for untreated extensive-stage small cell lung cancer patients after standard chemotherapy: a secondary analysis of CALGB 30504 (ALLIANCE)","volume":"11","author":"Salama","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.annonc.2025.09.008_bib181","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1158\/1078-0432.CCR-13-0306","article-title":"Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma","volume":"19","author":"Broniscer","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2025.09.008_bib182","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.ijrobp.2017.08.021","article-title":"Treatment-related noncontiguous radiologic changes in children with diffuse intrinsic pontine glioma treated with expanded irradiation fields and antiangiogenic therapy","volume":"99","author":"Patay","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.annonc.2025.09.008_bib183","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.radonc.2012.08.006","article-title":"EORTC 24051: unexpected side effects in a phase I study of TPF induction chemotherapy followed by chemoradiation with lapatinib, a dual EGFR\/ErbB2 inhibitor, in patients with locally advanced resectable larynx and hypopharynx squamous cell carcinoma","volume":"105","author":"Lalami","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.annonc.2025.09.008_bib184","first-page":"4085","article-title":"Concurrent palliative external radiotherapy with sorafenib or doxorubicin for bulky differentiated thyroid carcinoma: a case report","volume":"16","author":"Cortes-Mateus","year":"2018","journal-title":"Oncol Lett"},{"key":"10.1016\/j.annonc.2025.09.008_bib185","doi-asserted-by":"crossref","first-page":"1152-e98","DOI":"10.1634\/theoncologist.2017-0186","article-title":"A phase II study with lead-in safety cohort of 5-fluorouracil, oxaliplatin, and lapatinib in combination with radiation therapy as neoadjuvant Treatment for patients with localized HER2-positive esophagogastric adenocarcinomas","volume":"22","author":"Shepard","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.annonc.2025.09.008_bib186","doi-asserted-by":"crossref","first-page":"48586","DOI":"10.18632\/oncotarget.9374","article-title":"Simultaneous multitarget radiotherapy using helical tomotherapy and its combination with sorafenib for pulmonary metastases from hepatocellular carcinoma","volume":"7","author":"Sun","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.annonc.2025.09.008_bib187","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1007\/s00432-010-0821-z","article-title":"Feasibility of (125)I brachytherapy combined with sorafenib treatment in patients with multiple lung metastases after liver transplantation for hepatocellular carcinoma","volume":"136","author":"Li","year":"2010","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.annonc.2025.09.008_bib188","article-title":"Epigastric distress caused by esophageal candidiasis in 2 patients who received sorafenib plus radiotherapy for hepatocellular carcinoma","volume":"95","author":"Chen","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.annonc.2025.09.008_bib189","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1002\/cncr.24412","article-title":"Phase 1 study of concurrent sunitinib and image-guided radiotherapy followed by maintenance sunitinib for patients with oligometastases: acute toxicity and preliminary response","volume":"115","author":"Kao","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.annonc.2025.09.008_bib190","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.3892\/ol.2016.4851","article-title":"Effects of combined sunitinib and extracranial stereotactic radiotherapy on bone marrow hematopoiesis","volume":"12","author":"Kao","year":"2016","journal-title":"Oncol Lett"},{"key":"10.1016\/j.annonc.2025.09.008_bib191","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0036979","article-title":"Phase II trial of concurrent sunitinib and image-guided radiotherapy for oligometastases","volume":"7","author":"Tong","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.annonc.2025.09.008_bib192","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1345\/aph.1M469","article-title":"Bronchial fistula associated with sunitinib in a patient previously treated with radiation therapy","volume":"44","author":"Basille","year":"2010","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.annonc.2025.09.008_bib193","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.radonc.2017.01.018","article-title":"Phase I trial of radiation therapy and sorafenib in unresectable liver metastases","volume":"123","author":"Goody","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.annonc.2025.09.008_bib194","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.ijrobp.2015.11.048","article-title":"Phase 1 trial of sorafenib and stereotactic body radiation therapy for hepatocellular carcinoma","volume":"94","author":"Brade","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.annonc.2025.09.008_bib195","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.ijrobp.2015.12.015","article-title":"Changes in liver volume observed following sorafenib and liver radiation therapy","volume":"94","author":"Swaminath","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.annonc.2025.09.008_bib196","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.2169\/internalmedicine.9826-17","article-title":"The safety and efficacy of combination therapy of sorafenib and radiotherapy for advanced hepatocellular carcinoma: a retrospective study","volume":"57","author":"Wada","year":"2018","journal-title":"Intern Med"},{"key":"10.1016\/j.annonc.2025.09.008_bib197","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s00066-015-0873-8","article-title":"Prognostic indicators for radiotherapy of abdominal lymph node metastases from hepatocellular carcinoma","volume":"191","author":"Lee","year":"2015","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.annonc.2025.09.008_bib198","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.3349\/ymj.2013.54.5.1178","article-title":"Feasibility of sorafenib combined with local radiotherapy in advanced hepatocellular carcinoma","volume":"54","author":"Cha","year":"2013","journal-title":"Yonsei Med J"},{"key":"10.1016\/j.annonc.2025.09.008_bib199","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0082209","article-title":"A phase I, dose-finding study of sorafenib in combination with gemcitabine and radiation therapy in patients with unresectable pancreatic adenocarcinoma: a Grupo Espanol Multidisciplinario en Cancer Digestivo (GEMCAD) study","volume":"9","author":"Aparicio","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.annonc.2025.09.008_bib200","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.ijrobp.2014.02.024","article-title":"Phase 1 pharmacogenetic and pharmacodynamic study of sorafenib with concurrent radiation therapy and gemcitabine in locally advanced unresectable pancreatic cancer","volume":"89","author":"Chiorean","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.annonc.2025.09.008_bib201","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ijrobp.2015.09.009","article-title":"Sorafenib increases tumor hypoxia in cervical cancer patients treated with radiation therapy: results of a phase 1 clinical study","volume":"94","author":"Milosevic","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.annonc.2025.09.008_bib202","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/1477-7819-10-167","article-title":"Two cases of gastrointestinal perforation after radiotherapy in patients receiving tyrosine kinase inhibitor for advanced renal cell carcinoma","volume":"10","author":"Inoue","year":"2012","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.annonc.2025.09.008_bib203","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.prro.2019.02.012","article-title":"Hemorrhage from ascending colon and gluteal muscle associated with sorafenib and radiation therapy: radiation dose distribution corresponded with colonoscopy findings and computed tomography images","volume":"9","author":"Kashihara","year":"2019","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.annonc.2025.09.008_bib204","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3857\/roj.2017.00262","article-title":"Extraordinary radiation super-sensitivity accompanying with sorafenib combination therapy: what lies beneath?","volume":"35","author":"Lee","year":"2017","journal-title":"Radiat Oncol J"},{"key":"10.1016\/j.annonc.2025.09.008_bib205","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/s12328-015-0566-y","article-title":"Radiation-induced hemorrhagic duodenitis associated with sorafenib treatment","volume":"8","author":"Yanai","year":"2015","journal-title":"Clin J Gastroenterol"},{"key":"10.1016\/j.annonc.2025.09.008_bib206","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1016\/S0140-6736(02)09292-9","article-title":"Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial","volume":"359","author":"O\u2019Sullivan","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.annonc.2025.09.008_bib207","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.bjmsu.2009.11.003","article-title":"Small bowel perforation in a patient with metastatic renal cancer treated with radiotherapy and sunitinib","volume":"3","author":"Kwan","year":"2010","journal-title":"Br J Med Surg Urol"},{"key":"10.1016\/j.annonc.2025.09.008_bib208","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1038\/bjc.2014.537","article-title":"A phase Ib\/II translational study of sunitinib with neoadjuvant radiotherapy in soft-tissue sarcoma","volume":"111","author":"Lewin","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.annonc.2025.09.008_bib209","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1158\/1078-0432.CCR-18-2466","article-title":"Clinical development of novel drug-radiotherapy combinations","volume":"25","author":"Ahmad","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2025.09.008_bib210","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nrclinonc.2016.79","article-title":"Clinical development of new drug-radiotherapy combinations","volume":"13","author":"Sharma","year":"2016","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753425047192?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753425047192?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T20:59:46Z","timestamp":1777582786000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753425047192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":210,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0923753425047192"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2025.09.008","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ESMO\u2013ESTRO consensus statements on the safety of combining radiotherapy with immune checkpoint inhibitors, VEGF(R) inhibitors, or multitargeted tyrosine kinase inhibitors","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2025.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}